Klygefa (gefurulimab)
- Region
- 🇺🇸 US
- Active substance
- gefurulimab
- Company
- Alexion Pharm
- Status
- Approved
- FDA approval
- Fri 13 Nov 2026
- Designations
- New biologic
- Application
- BLA761488
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Klygefa (gefurulimab): expected EC decision
Estimated as CHMP opinion (2026-09-17) + 67 days, the standard Commission decision period. Not an official date. · Alexion Europe · source
FDA approves Klygefa (gefurulimab), a new medicine
Alexion Pharm; BLA761488; New biologic; solution · source
Klygefa (gefurulimab): CHMP positive opinion
In-depth analysis
Where it stands
Klygefa (gefurulimab), from Alexion Pharm, is recorded as approved in the US. The FDA approval is dated 2026-11-13 under BLA761488. The product is a new biologic supplied as a solution.
In the EU, the same substance is at the opinion stage. The CHMP issued a positive opinion on 2026-09-17, with Alexion Europe listed as the applicant. No EC decision is recorded as official yet.
The records do not state the therapeutic area or the approved indication, so this analysis cannot say which patients the product is for or what the labelled use is. The header's CHMP opinion date field is blank, but the milestone list does show the 2026-09-17 opinion. I treat the milestone entry as the more specific source.
Regulatory pathway and designations
In the US, the product went through a Biologics License Application (BLA), which is the standard route for a new biologic. The only designation recorded is 'New biologic'. The records show no orphan, breakthrough, priority review, fast track or accelerated approval status, and I do not infer any.
In the EU, a positive CHMP opinion is a scientific recommendation. It is not itself a marketing authorisation. The European Commission normally adopts a legally binding decision within about 67 days of the opinion, and that decision makes the product legally marketable across EU member states.
The records give an expected EC decision date of 2026-11-23. It is calculated as the CHMP opinion date plus 67 days, and the date arithmetic is consistent. It is flagged as an estimate and not an official date, so it should not be treated as a confirmed timeline. The records do not say whether the EU application is under standard or accelerated assessment, or whether any conditional or exceptional-circumstances route applies.
Safety and pharmacovigilance
The records contain no safety information. They do not cover boxed warnings, contraindications, adverse event profiles, a REMS, risk management plan content, or post-marketing commitments.
Safety assessment of this product therefore needs the FDA label and approval documents, and the EU CHMP assessment report and product information once they are published.
What to watch
The main near-term item is the European Commission decision. The records estimate it around 2026-11-23, and the official decision date should be checked against the Union Register of medicinal products.
Other items to check once the documents are available:
- The full FDA label and review documents, to confirm the indication, dosing, warnings and any postmarketing requirements.
- The EU product information and assessment report, to see whether the EU and US indications align.
- Any later regulatory activity in other regions. The records show only the US and EU entries.
AI-generated on 2026-11-17 from the official records on this page (model claude-sonnet-5-5). It can contain errors: check the sources.
Same substance in other markets
- 🇪🇺 Klygefa Opinion · Alexion Europe
Follow Klygefa
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.